baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Argenx SE/ NL0010832176 /

5/2/2024 5:19:44 PM	Chg. +19.25	Volume	Bid5:30:00 PM	Ask5:30:00 PM	Market Capitalization	Dividend Y.	P/E Ratio
363.40EUR	+5.59%	560 Turnover: 201,526	-Bid Size: -	-Ask Size: -	21.46 bill.EUR	-	-

GlobeNewswire 5/2 argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024

GlobeNewswire 4/16 argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Pa...

GlobeNewswire 3/27 argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

GlobeNewswire 3/26 argenx Announces Annual General Meeting of Shareholders on May 7, 2024

GlobeNewswire 3/26 argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thr...

GlobeNewswire 3/7 argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of ...

GlobeNewswire 2/29 argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

GlobeNewswire 2/26 argenx to Present at Upcoming Investor Conferences

GlobeNewswire 2/22 argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29,...

GlobeNewswire 2/20 argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review f...

GlobeNewswire 2/14 Genmab Publishes 2023 Annual Report

GlobeNewswire 1/18 argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcu...

GlobeNewswire 1/8 argenx Highlights 2024 Strategic Priorities

GlobeNewswire 1/2 argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 12/7/2023 TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commerci...

GlobeNewswire 11/28/2023 argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocyt...

GlobeNewswire 11/16/2023 argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Gene...

GlobeNewswire 11/13/2023 RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire 11/9/2023 X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates

GlobeNewswire 11/7/2023 Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates

GlobeNewswire 11/1/2023 RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors

GlobeNewswire 11/1/2023 argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scie...

GlobeNewswire 11/1/2023 argenx to Present at Upcoming Investor Conferences

GlobeNewswire 10/31/2023 argenx Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire 10/24/2023 argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023

Argenx SE/ NL0010832176 /

If you wish to receive reply to your feedback, please provide your email address.